Evolution of the imCORE Network during and post the COVID-19 pandemic: shifting priorities in oncology clinical trials.

IF 3 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2025-06-17 DOI:10.1080/14796694.2025.2520147

Sarah Helou, Tanya Vidhyarkorn, San Tran, Catherine Scher, Sarah Churchill, Janice Russell

{"title":"Evolution of the imCORE Network during and post the COVID-19 pandemic: shifting priorities in oncology clinical trials.","authors":"Sarah Helou, Tanya Vidhyarkorn, San Tran, Catherine Scher, Sarah Churchill, Janice Russell","doi":"10.1080/14796694.2025.2520147","DOIUrl":null,"url":null,"abstract":"Background: The immunotherapy Centers of Research Excellence (imCORE) Network is a worldwide research network. Pre-coronavirus disease 19 (COVID-19) pandemic, the Network established itself as a partnership model leader with several years of experience. COVID-19 directly impacted clinical research conduct, imCORE sites, patients, and how the network operates.Methods: The sponsor created a survey assessing operational priorities of Network sites pre-COVID-19, immediately post-COVID-19, and present day. The survey asked each site to prioritize 14 operational aspects of clinical research at the three separate timepoints allowing for data comparison between the timepoints.Results: This paper highlights the impacts of COVID-19 to the operational priorities of imCORE sites. This includes specific measures taken to evolve to fit the needs of its sites and their patients, and presents a path forward for site networks to consider in the new reality of COVID-19 era clinical trials.Conclusions: Site networks positively impacted site knowledge and experience through the pandemic and beyond. Sponsors must recognize each site as a unique entity with their own priorities and focus while understanding a commonality of priorities within regions and among research sites globally. We recommend the creation of site networks to further strengthen the sponsor-site relationship.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-6"},"PeriodicalIF":3.0000,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2025.2520147","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The immunotherapy Centers of Research Excellence (imCORE) Network is a worldwide research network. Pre-coronavirus disease 19 (COVID-19) pandemic, the Network established itself as a partnership model leader with several years of experience. COVID-19 directly impacted clinical research conduct, imCORE sites, patients, and how the network operates.

Methods: The sponsor created a survey assessing operational priorities of Network sites pre-COVID-19, immediately post-COVID-19, and present day. The survey asked each site to prioritize 14 operational aspects of clinical research at the three separate timepoints allowing for data comparison between the timepoints.

Results: This paper highlights the impacts of COVID-19 to the operational priorities of imCORE sites. This includes specific measures taken to evolve to fit the needs of its sites and their patients, and presents a path forward for site networks to consider in the new reality of COVID-19 era clinical trials.

Conclusions: Site networks positively impacted site knowledge and experience through the pandemic and beyond. Sponsors must recognize each site as a unique entity with their own priorities and focus while understanding a commonality of priorities within regions and among research sites globally. We recommend the creation of site networks to further strengthen the sponsor-site relationship.

查看原文本刊更多论文

COVID-19大流行期间和之后imCORE网络的演变：肿瘤学临床试验重点的转移

背景：免疫治疗卓越研究中心（imCORE）网络是一个全球性的研究网络。在2019冠状病毒病（COVID-19）大流行之前，该网络已成为具有多年经验的伙伴关系模式领导者。COVID-19直接影响了临床研究行为、imCORE站点、患者以及网络的运作方式。方法：发起人创建了一项调查，评估网络站点在covid -19之前，covid -19之后和现在的运营优先级。该调查要求每个站点在三个独立的时间点优先考虑临床研究的14个操作方面，以便在时间点之间进行数据比较。结果：本文重点分析了新冠肺炎疫情对imCORE站点业务重点的影响。这包括为适应其站点及其患者的需求而采取的具体措施，并为站点网络在COVID-19时代临床试验的新现实中提供了一条前进的道路。结论：站点网络在大流行期间及以后对站点知识和经验产生了积极影响。赞助商必须认识到每个站点都是一个独特的实体，有自己的优先事项和重点，同时理解区域内和全球研究站点之间优先事项的共性。我们建议建立网站网络，以进一步加强赞助商与网站的关系。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.